Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
CLOROX CO /DE/
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-69.4% vs price
Base Case (Median)
-34.3% vs price
Bull Case (75th pct.)
5.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $88.40 | 9.9% | Medium (25%) |
| Growth Trajectory DCF | $74.20 | -7.8% | Medium (20%) |
| Graham Number | $8.94 | -88.9% | High (80%) |
| EV/EBITDA | $31.48 | -60.9% | Medium (20%) |
| EV/FCF | $22.36 | -72.2% | Medium (20%) |
| Earnings Power Value | $260.72 | 224.1% | High (70%) |
Based on 6 out of 7 methods, CLX appears fairly valued at the current price of $80.45. The base case fair value of $52.84 implies 34.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.